1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd

300683.SZ
Wuhan Hiteck Biological Pharma Co.,LtdCN flagShenzhen Stock Exchange
25.90
CNY
-1.62
- -
3.39BMarket Cap

Total Valuation

Wuhan Hiteck Biological Pharma Co.,Ltd carries a market capitalization of 3.39B, placing it among publicly traded companies globally. Its enterprise value stands at 2.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.39B
Enterprise Value2.58B

Share Statistics

Wuhan Hiteck Biological Pharma Co.,Ltd currently has 130.89M shares outstanding.

Shares Outstanding130.89M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 5.09, and the price-to-book ratio stands at 7.06.

PE RatioN/A
PS Ratio5.09
PB Ratio7.06
P/TBV Ratio1.77
P/FCF Ratio66.60
P/OCF RatioN/A

Enterprise Valuation

EV / Sales4.03
EV / EBITDAN/A
EV / EBITN/A
EV / FCF51.09

Financial Position

Wuhan Hiteck Biological Pharma Co.,Ltd maintains a current ratio of 4.89, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.72, indicating elevated leverage, while an interest coverage ratio of -51.54 demonstrates limited ability to service its debt obligations.

Current Ratio4.89
Quick Ratio3.06
Debt / Equity1.72
Debt / EBITDA-0.48
Interest Coverage-51.54

Financial Efficiency

Return on Equity (ROE)-16.72
Return on Assets (ROA)-2.99
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.42

Taxes

Income Tax-5.49M
Effective Tax RateN/A

Stock Price Statistics

Wuhan Hiteck Biological Pharma Co.,Ltd's stock has declined approximately -2.74127% over the past 52 weeks. The 50-day moving average sits at 29.76, while the 200-day moving average is 31.98.

Beta (5Y)N/A
52-Week Price Change-2.74127%
50-Day Moving Average29.76
200-Day Moving Average31.98
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Wuhan Hiteck Biological Pharma Co.,Ltd generated 639.41M in revenue and converted that into -85.76M in net income, yielding earnings per share of -0.71. EBITDA reached -84.15M, while operating income came in at -84.15M.

Revenue639.41M
Gross Profit259.83M
Operating Income-84.15M
Pretax Income-95.02M
Net Income-85.76M
EBITDA-84.15M
EBIT-84.15M
Earnings Per Share (EPS)-0.71

Balance Sheet

Wuhan Hiteck Biological Pharma Co.,Ltd holds 732.08M in cash and equivalents against 40.64M in total debt, resulting in a net debt position of -229.17M. Total book value stands at 460.79M, with working capital of 928.26M providing operational flexibility.

Cash & Cash Equivalents732.08M
Total Debt40.64M
Net Debt-229.17M
Equity (Book Value)460.79M
Book Value Per Share3.64
Working Capital928.26M

Cash Flow

After subtracting -48.87M in capital expenditures, free cash flow totaled -48.87M - equivalent to -0.39 per share.

Operating Cash FlowN/A
Capital Expenditures-48.87M
Free Cash Flow-48.87M
FCF Per Share-0.39

Margins

Wuhan Hiteck Biological Pharma Co.,Ltd operates with a gross margin of 40.64, reflecting its pricing power and cost economics. The operating margin of -13.16 and net profit margin of -13.41 provide insight into operational efficiency.

Gross Margin40.64
Operating Margin-13.16
Pretax Margin-14.86
Profit Margin-13.41
EBITDA Margin-13.16

Dividends & Yields

The company's payout ratio of -19.53 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.14
Dividend YieldN/A
Payout Ratio-19.53
Shareholder Yield0.68
FCF Yield1.50

Scores

Wuhan Hiteck Biological Pharma Co.,Ltd posts an Altman Z-Score of 5.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.65